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Background: Controlling hypertension rates and maintaining normal blood pressure, particularly in resource-constrained
settings, represent ongoing challenges of effective and affordable implementation in health care. One of the strategies
being largely advocated to improve high blood pressure calls for salt reduction strategies. This study aims to estimate the
impact of a population-level intervention based on sodium reduction and potassium increase – in practice, introducing a
low-sodium, high-potassium salt substitute – on adult blood pressure levels.
Methods/Design: The proposed implementation research study includes two components: Phase 1, an exploratory
component, and Phase 2, an intervention component. The exploratory component involves a triangle taste test and a
formative research study designed to gain an understanding of the best implementation methods. Phase 2 involves a
pragmatic stepped wedge trial design where the intervention will be progressively implemented in several clusters
starting the intervention randomly at different times. In addition, we will evaluate the implementation strategy using a
cost-effectiveness analysis.
Discussion: This is the first project in a Latin-American setting to implement a salt substitution intervention at the
population level to tackle high blood pressure. Data generated and lessons learnt from this study will provide a strong
platform to address potential interventions applicable to other similar low- and middle-income settings.
Trial registration: This study is registered in ClinicalTrials.gov NCT01960972.
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Hypertension is a silent condition and a major worldwide
contributor to the growing pandemic of cardiovascular
disease (CVD) and stroke, especially in low- and middle-
income countries (LMIC) [1-3]. Poor control rates for
hypertension and appropriate strategies to maintain nor-
mal blood pressure, particularly in resource-constrained
settings, reflect the challenge of effective and affordable
implementation in health care systems.
One of the policies being advocated by both inter-
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article, unless otherwise stated.the implementation of salt reduction strategies [4,5].
This approach is applicable not only to LMIC but also
established economies. The Institute of Medicine labeled
hypertension as a ‘neglected disease’ and recommended
salt-reduction strategies at the population level as the way
forward [6,7].
A decade ago, the Prospective Studies Collaboration
conducted a meta-analysis of 61 observational studies of
blood pressure and vascular disease in adults and found
that for each 2 mmHg decrease in systolic blood pres-
sure, stroke mortality and cardiovascular mortality de-
creased by 10% and 7%, respectively, an effect that was
observed in reductions of systolic blood pressure levels
up to 115 mmHg [8]. This indicates that small changes
in blood pressure at the population level could result in
large public health gains. The main challenge, however,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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under real life conditions while acknowledging the po-
tential impact of local contexts.
Sodium chloride has been the subject of intense scien-
tific research aimed at understanding its impact on health,
especially on blood pressure [9-14]. Although criticized
because of a biased approach [15], the Committee on the
Consequences of Sodium Reduction in Populations con-
vened by the Institute of Medicine reported that existing
studies that explore the impact of salt reduction strategies
on health are less than optimal [6]. A recent systematic re-
view assessing the effect of modest reduction in salt intake
on blood pressure supports the need of reducing salt [10].
Two previous studies, one in Tibet [16] and another in
rural China [17], have demonstrated the potential effect
of salt substitution on blood pressure among individuals
with diagnosed hypertension; however, to our knowledge,
limited evidence regarding this effect is available at the
population level.
The most recent WHO guidelines regarding sodium
intake for adults and children [18] strongly recommend
a reduction to less than 5 grams/day of salt among adults
with or without hypertension. Yet, the successful imple-
mentation of this recommendation, especially in develop-
ing countries, might be difficult to achieve without taking
into account the role of salt on palatability of foods associ-
ated with taste [19,20]. In Peru, no accurate data exists
about the sources of salt consumption [21]. Based on our
pilot studies, salt added during cooking, rather than proc-
essed foods, appears as the main source of salt intake.
Monitoring salt intake in both developing and developed
countries poses major practical challenges [22]. In the
Peruvian context, salt reduction strategies do have a role
and should be addressed through their own channels. Such
an approach does not conflict with salt substitution inter-
ventions, since cooking practices are highly prevalent and
thus amenable to achieve changes in patterns of overall
salt intake.
This study protocol addresses both ongoing scientific
and practical implementation challenges by estimating
the impact of a population-level intervention based on
reducing sodium and increasing potassium – in practice,
introducing a low-sodium, high-potassium salt substitute –
on adult blood pressure levels. The information gathered
in this study will provide strong, locally relevant informa-
tion that may be applicable to other similar settings in
Latin America and elsewhere.
Methods/Design
Objectives
This study aims to bridge a gap in implementation re-
search by reducing blood pressure levels at the population
level through the introduction of a community-wide inter-
vention with a low-sodium, high-potassium salt substitutein a resource-constrained setting. Accordingly, the specific
objectives of this study protocol are: i) to assess patterns
of predisposition towards incorporating a salt substitute
into daily cooking among villagers, authorities, and other
potential stakeholders, in order to inform the structure of
the intervention in the local communities and ensure suc-
cessful implementation; ii) to implement and assess the
impact of an intervention using a salt substitute on blood
pressure at the population level using a stepped wedge trial
design; and iii) to determine, if successful, the cost of this
implementation and the incremental cost-effectiveness
ratio of our intervention.
Study design
The proposed implementation research study includes
an exploratory component and a field intervention com-
ponent. The intervention involves a pragmatic stepped
wedge trial design, such that we will progressively imple-
ment our intervention at random in several clusters [23]
following an introductory period oriented to gaining an
understanding of the best implementation methods. The
study will include both qualitative and quantitative meth-
odologies for collecting baseline information, and moni-
toring the impact of the intervention during rollout and at
its conclusion.
Setting and time frame
This study involves inhabitants from Tumbes, a depart-
ment located in the north coastal region of Peru on the
border with Ecuador. The semi-urban area of Tumbes
consists of more than 100 villages of varying size with
an approximate total population of 80,000. It is com-
prised of a large ‘mestizo’ – mixed of European and
Amerindian ancestry – population, and the traditional
agricultural and fishing landscape has become inter-
mixed with rapidly growing urban sections. Illiteracy rate
is around 10%, and 50% of the inhabitants have no
health insurance. Activities related to this protocol began
in 2012 and are expected to continue through 2017.
Participant recruitment and selection criteria
Participants from six randomly-selected villages will be
involved in the different phases of the study. Potentially
eligible subjects will be identified from the most updated
census available. Males or females aged 18 years and over
from the randomly selected villages, capable of under-
standing study procedures, capable of providing informed
consent, and full-time residents in the area are eligible.
Only those participants with mental illness that impair
their consent will be excluded. In the case of the stepped
wedge trial, self-reported history of chronic kidney disease
and heart disease will be considered as additional exclu-
sion criteria.
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To accomplish the proposed objectives, this protocol has
two phases:Phase 1: Exploratory phase
This component includes a triangle taste test and a for-
mative qualitative research study that will generate the
elements to create a social marketing campaign before
the intervention’s implementation.Triangle taste test This test is a discriminative form of
a sensory analysis that may indicate whether or not a de-
tectable difference in taste exists between two samples
[24]. Common salt, 100% sodium chloride, will be com-
pared to salt substitute samples containing different po-
tassium chloride concentrations: 25%, 33%, and 50%,
with the consequent reduction in sodium. This experi-
ment will allow the assessment of acceptability of taste
of the salt substitutes compared to common salt. Partici-
pants will be exposed to three coded food samples, two
identical and one different (odd). Subjects will taste each
sample in a random order, to avoid positional bias, and
will be instructed to identify the odd sample [25].Formative research This component will combine focus
groups and in-depth interview research techniques with
a wide range of participants from the community includ-
ing inhabitants, commercial traders, and stakeholders such
as staff from the health care system as well as local author-
ities. In this way, we will guarantee a diversity of points of
view regarding ordinary salt, high blood pressure, and
CVD to create an appropriate marketing campaign to
increase the likelihood of the acceptance of the salt sub-
stitute. The focus groups will include inhabitants from
different villages, while in-depth interviews will be con-
ducted with individuals with hypertension and stake-
holders. The stakeholders include, but are not limited to,
community health leaders and health promoters, local
authorities (village representatives, health authorities, etc.),
health workers (physicians, nurses, and health techni-
cians), and commercial traders (restaurant owners, street
vendors, community kitchen members, bakers, shop-
keepers, etc.).Social marketing campaign The goal of this campaign
is to introduce participants to the salt substitute prior to
and during the intervention in order to enhance its ac-
ceptance. Thus, villagers and stakeholders will be ac-
tively invited to develop and later be exposed to social
marketing techniques designed to encourage the salt
substitute consumption.Phase 2: Intervention and implementation activities
Baseline data collection This information will be col-
lected immediately before implementing activities in all
participant villages. We plan to collect baseline informa-
tion of participants at the individual- and family-level. We
will use a modified version of the WHO STEP approach
questionnaire for surveillance of non-communicable dis-
eases [26]. Questions related to salt intake have also been
included in these instruments. Ideally, salt intake should
be assessed in urine and this is a limitation of our prag-
matic design. We will indirectly evaluate salt intake
consumption patterns by weighing salt containers in
households. In addition, this baseline will include a
clinical assessment to measure blood pressure in tripli-
cate using standardized procedures with automated
validated devices, and weight and height using stan-
dardized techniques and procedures. Costs-related
data will also be collected at baseline in order to in-
form cost-effectiveness analysis at a later stage. A
summary of the data collected at baseline is shown in
Table 1.Intervention and implementation activities Salt re-
placement will be progressively implemented over six
months in each village. The intervention will contemplate
interactions with families as well as bakeries, community
kitchens, food vendors including street vendors, and restau-
rants. Ideally, replacement will require a complete exchange
of ordinary salt. The assessments of salt consumption will
be carried out using questionnaires and weighing of salt
containers at randomly selected households over time, and
also by evaluating supply chain management indicators
such as rate of delivery of the salt substitute to each family
or food vendors.
Because of logistical constraints, especially around intro-
ducing and sustaining an adequate social marketing cam-
paign together with the salt substitute delivery, the
intervention can only be implemented in stages. Thus,
the stepped wedge trial is an optimal design to ensure
both moral and social acceptability. As described by
Brown [23], “in a stepped wedge design, an intervention
is rolled-out sequentially to participants (either as indi-
viduals or clusters of individuals) over a number of time
periods. The order in which the different individuals
or clusters receive the intervention is determined at
random and, by the end of the random allocation, all
individuals or groups will have received the interven-
tion. Stepped wedge designs incorporate data collection
at each point where a new group (step) receives the
intervention”. In Table 2, villages receiving the inter-
vention are indicated with the number 1, and those
villages not receiving the intervention are indicated
with a 0.
Table 2 Stepped wedge design for the proposed study
Clusters
Time period
1 2 3 4 5 6 7
Village 1 0 1 1 1 1 1 1
Village 2 0 0 1 1 1 1 1
Village 3 0 0 0 1 1 1 1
Village 4 0 0 0 0 1 1 1
Village 5 0 0 0 0 0 1 1
Village 6 0 0 0 0 0 0 1
Table 1 Sections and topics of the questionnaire in
the study
Section Components
Demographic assessment form: - Place and date
- Consent process
- Contact information
Sociodemographic information form: - Demographic information
- Health coverage
Household information form: - Family characteristics
- Expenditures
- Change attitudes
- History of blood
pressure measurements
Knowledge about salt and
high blood pressure:
- Knowledge about high
blood pressure
- Salt consumption
- Household information: assets




- Lack of activity
Mental health assessment form: - Depressive symptoms
- Quality of life
- Stress
- Sleep patterns
Cardiovascular assessment form: - Cardiovascular medication
- Personal and familiar history
- Memory
- Stroke
Clinical measurements form: - Height
- Weight
- Waist and hip circumference
- Blood pressure
Costing data form: - Patient costs
- Program costs
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tation process, clusters will be randomly allocated a time
when they are going to receive the intervention. Accord-
ing to the CONSORT guidelines extended to cluster ran-
domized trials, the statistician will randomize the cluster
using computer generated random numbers [27]. Only
the research team will be aware of the allocation of all of
the clusters. In order to keep allocation concealment, vil-
lage inhabitants will be informed of the allocation time at
the moment of the implementation in their cluster.
Due to the nature of the intervention, it will be not
possible to blind inhabitants to the intervention. How-
ever, outcomes will be assessed by a different fieldwork
team blinded to the intervention.
Periodical assessments These will include data collec-
tion regarding costs and clinical measurements. Every five
to six months, once a new village commences on the
intervention, a new evaluation will be performed in all
participant villages, both intervention and control. Clinical
measurements will include systolic and diastolic blood
pressure, height, and weight. These periodic assessments
will be performed at each household to guarantee contact
with each family member enrolled in this study.
Cost-effectiveness analysis For this component, we will
be interested in total cost of the implementation, including
costs of the substitute itself and other associated costs due
to transportation, delivery, and consumption frequency.
We will also evaluate costs associated with the marketing
and engagement campaign as well as capital costs. In-
formation will be collected at the baseline but also in
each of the periodic assessments. Thus, an incremental
cost-effectiveness analysis as well as the additional cost
to avoid an increase of 1 mmHg at the population level
will be performed, comparing to the cost of using ordin-
ary salt. This involves the estimation of the discrepancy
in costs between the two contexts, ordinary salt and salt
substitute consumption, and the difference of mmHg
increase in each case.
Sample size
Triangle taste test
Given that three coded food samples will be presented to
each participant, two similar and one odd, there is a prob-
ability of 33% of randomly selecting the appropriate sam-
ple. However, if a participant can differentiate between the
two types of samples, since two are similar, the actual
probability is 50%. Assuming a significance level of 5%
and a power of 90%, approximately 146 participants will
be required, as described previously elsewhere [25].
Formative research For this component, approximately
228 participants are needed to have enough opinions in
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60). Focus groups will include healthy and hypertensive
participants from different villages stratified by sex and
age (20 to 44 and 45 to 65 years old). Separately, in-
depth interviews will be conducted among hypertensive
individuals as well as community or local stakeholders.
We expect to enroll approximately 10 participants from
each village for the interviews. Of these, 5 will be indi-
viduals with hypertension, whereas the other 5 will be
stakeholders, e.g., community health leaders and author-
ities, commercial traders, health workers, and others.
Stepped wedge trial
Calculations were derived using preliminary data from
the baseline of the CRONICAS cohort study in Tumbes
[28] and the PERU MIGRANT study estimates [29]. Power
for the stepped wedge design was computed for a continu-
ous endpoint [30], where X is a N x T matrix showing the
treatment pattern, i.e., Xij = 1 if cluster ‘i’ received the inter-
vention at time ‘j’ and 0 otherwise. We assumed a signifi-
cance level of 5%, a standard deviation of blood pressure
within sites of 20 mmHg (σ), the number of clusters (N) as
6, the number of time periods (T) as 6 (excluding baseline
assessment), the average number of subjects assessed per
cluster and time period as 300, and τ, an approximation to
the coefficient of variation, as 0.20. Based on those as-
sumptions, we calculated a power over 90% to find a differ-
ence (θ) of 3 mmHg in blood pressure levels between the
intervention and control groups. This magnitude of differ-
ence is within the expected range that provides major pub-
lic health gains in the long-term, in particular in reduction
of stroke [8]. Typically, the coefficient of variation ranges
between 0.15 and 0.40, but when this value is unknown, as
in this study, sensitivity of the sample size within this range
needs to be verified [31]. In this protocol, power calcula-
tions using both extremes of coefficient of variation yields
a power greater than 90%.
Statistical analysis
Triangle taste test
We will be able to determine whether the total number
of correct responses for the total number of participants
is statistically significant based on the critical number of
correct responses in a triangle taste test. Thus, there is a
one out of three chance that the correct (odd) sample
will be picked just by chance (guessing). We will then
compute a z-statistic based on the following formula:
z ¼ k− n=3ð Þð Þﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2n=9
p
In this formula, ‘n’ is the total number of subjects
assessed and ‘k’ is the number of correct responses [32].
Based on these results, we will reject the hypothesis of‘no difference’ between samples if the number of correct
responses is significantly greater than the calculated
value (z).
Qualitative data Information from focus group sessions
and in-depth interviews will be recorded and transcribed.
All the collected information will be segmented, entered,
coded, and analyzed using Atlas.Ti to identify a list of rele-
vant themes and thus, identify key concepts to create our
social marketing campaign. Coding will be carried out
using the grounded theory approach to data analysis,
where the data emerges from the participants, not the re-
searchers [33,34]. The analysis will compare the informa-
tion obtained from different subgroups of participants in
order to identify and describe the similarities and diver-
gences between men and women, patients from different
age groups, and health workers and stakeholders. The
analysis will also include notes from the field, i.e., field-
work diary and minutes of the researchers’ meetings.
Stepped wedge trial design
Descriptive and exploratory statistics using tabulations
and graphical methods will be derived. This process will
allow us to verify the data entry process as well to detect
atypical values. Following careful checking, we will describe
variables of interest, especially our numeric outcome, using
appropriate central tendency measures (mean, median,
etc.) and dispersion measures (standard deviation, inter-
quartile range, etc.). Appropriate longitudinal and panel
data analysis techniques will be used for the assessment of
blood pressure levels from baseline to the end of the study.
Since cluster sizes may vary, an efficient analysis at the
cluster mean level requires weights that depend on un-
known parameters. Thus, an analysis at the individual level
using generalized estimating equations (GEE) or general-
ized linear mixed models are preferable. Of these, GEE can
flexibly handle normal or non-normal endpoints and tends
to be more robust to misspecification of the variance struc-
ture since ‘sandwich’ type variance estimates are used [35].
In the same sense, GEE uses within-cluster and between-
cluster information to estimate the treatment effect. This
approach is necessary to avoid confounding the treatment
effect with changes over time [36].
Economic evaluation Cost effectiveness analysis can be
used as a tool for measuring costs and health gains of in-
terventions, which in turn can help in decision-making
and resource allocation. At the first stage, we will de-
velop a cost analysis associated with the patient costs
and the program implementation. Patient costs involve
costs of illness data for treating high blood pressure or
its complications, i.e., cardiovascular drugs, medical visits,
hospitalization, laboratory tests, special diets, physical ther-
apies, blood pressure caregiving, and monitors and other
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paign, training, administration, production, and delivery of
the salt substitute, among other activities. Our effect in-
dicators will be measured by different health outcomes:
blood pressure level (mmHg), number of cases averted
(CVDs and stroke), and disability-adjusted life years
averted. An incremental cost effectiveness ratio will show
us the additional cost of a unit of health gained. Our cost-
effectiveness analysis methodology will follow the guidelines
established by WHO-CHOICE [37] and recommendations
given by the Disease Control Priorities Project [38].
Ethical issues
This project was reviewed and approved by Institutional
Review Boards at Universidad Peruana Cayetano Heredia
(Peru) and Johns Hopkins University (USA). Informed
consent for participation will be obtained from all hu-
man subjects prior to subject participation and confiden-
tiality of subjects will be protected.
All study participants will be linked to a unique identi-
fication code. Data will be recorded both in paper form
and electronically. The electronic information will be
stored, backed up, and secured by password protection.
Paper forms will be stored in secure locked cabinets. All
personal information, including participant’s names, ad-
dresses, and dates of birth, will be stored in a file and
password protected as well. Only study investigators will
have access to confidential information.
Discussion
Developing effective pragmatic preventive strategies
for chronic non-communicable diseases in resource-
constrained settings is a challenge that needs to be ad-
dressed. In addition, there has been little research
coverage and discussion of non-clinical, population-
based approaches as an avenue to tackle CVDs in de-
veloping settings [39]. Therefore, our understanding
of non-pharmacological intervention strategies for non-
communicable diseases, such as hypertension, in resource-
poor settings is limited, if not absent.
The complex context of LMIC can provide a variety of
scenarios that could identify new areas for innovation,
relevant at both local and international levels. For ex-
ample, there are both challenges and opportunities related
to salt substitution in Peru. A previous successful public
health measure involved promoting iodine-supplemented
salt as a vehicle to prevent iodine deficit disorders, such
as goiter [40], and in commercial spheres, the slogan
“Consuma salud… consuma sal”, or “Buy health… buy salt”,
is being promoted. This is a challenge for our intervention
because salt has been marketed as a positive health meas-
ure, and we now propose to promote the replacement of
regular salt with a substitute. Changes associated with
growth and urbanization also poses an additional challengefor implementation research. However, these circumstances
also provide an opportunity, because the success of this
measure demonstrates the successful collaboration of gov-
ernment and industry in Peru. This underscores the im-
portance and relevance of understanding the local context,
and we can utilize this knowledge taking advantage of this
past successful partnership to explore the introduction of a
salt substitute to be tested at a wide community interven-
tion. Thus, the data gathered in this study will provide a
strong platform to address potential interventions that are
locally relevant and that could be applicable to other set-
tings in Latin America and, eventually, to settings in other
LMIC countries.
Previous reports demonstrated that salt reduction may
play an important role in reducing blood pressure levels
among hypertensive and normotensive people [13,41,42],
and may reduce cardiovascular disease [43]. Similarly,
the increase of dietary potassium can reduce mean systolic
and diastolic blood pressure levels [44,45], and could con-
tribute to the prevention of hypertension, especially in
populations with elevated blood pressure [13,46]. How-
ever, as pointed out by the Committee on the Conse-
quences of Sodium Reduction in Populations [6], most of
the evidence on clinical outcomes came from observa-
tional prospective cohort studies. Moreover, data examin-
ing the effect of dietary sodium in combination with other
electrolytes, particularly potassium, on health outcomes, is
needed [6]. Thus, the results of this study are of potential
interest as an approach to gradually reduce sodium intake
in resource-constrained settings.
In most developed countries, a reduction in salt intake
can be achieved by a gradual and sustained reduction in
the amount of salt added to food by the food industry.
In other countries, especially LMIC, where most of the
salt consumed comes from salt added during cooking or
from sauces, a different public health campaign would
be required to encourage consumers to use less salt [47].
The study described here may be the first pragmatic
intervention in a Latin-American country to implement
a salt substitute at the population level, and it could
yield a significant impact on public health. Replacing or-
dinary salt with a substitute containing low-sodium and
high-potassium significantly reduced blood pressure levels
among hypertensive participants of a randomized con-
trolled trial conducted in a clinical setting in Tibet [16], as
well as hypertensive and normotensive participants in rural
areas of China [17,48]. In consequence, a salt substitute
may be an effective adjuvant treatment for patients with
hypertension and effective in preventing hypertension in
normotensive individuals. Nevertheless, population-based
approaches are needed to guarantee appropriate scaling-up
in other contexts.
Strategies for salt intake reduction have been addressed
as potentially very cost-effective measures [49]. In the
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salt intake, would have an effect in the entire population.
Therefore, including larger population groups as benefi-
ciaries of preventative interventions, and not only high-
risk individuals, might render such approaches attractive
because it could be more cost-effective. In the same vein,
scaling up this intervention at the population level might
offer a very simple, low-cost lifestyle approach to blood
pressure reduction and control in resource-constrained
settings [39].
The development and evaluation of a strategy for imple-
menting the salt substitute at the community level, with
participation of multiple stakeholders, will produce strong
evidence to aid policy makers and public health specialists
in the implementation of affordable prevention strategies
at a LMIC level [50]. Our results will include a cost-
effectiveness analysis component, which will provide more
arguments for the policy debate. In planning for scalabil-
ity, we are involving key decision makers at the central
government level. We have also initiated communications
with Peru’s Parliament representatives in order to make
them aware, early in the process of research, of the poten-
tial public gains of these types of interventions. Closer to
the health sector, we have enabled the interaction of the
Peruvian Society for Nutrition as well as the Peruvian
National Institute of Health. The latter is already tasked
with ongoing monitoring of the salt supplementation
with iodine, and will be a key foundation partner to ex-
plore potential links and discussions with industry.
Trial status
Both phases of the study protocol have been reviewed
and granted approval by the Institutional Review Boards
at Universidad Peruana Cayetano Heredia and Johns
Hopkins University. This study has been registered as a
clinical trial (NCT01960972). As of this manuscript sub-
mission, we have completed Phase 1 of the project, and
we plan to start Phase 2, enrollment into the stepped
wedge trial, in March 2014.
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